Grant of Options & Director/PDMR Dealing
4basebio PLC announced the grant of 684,872 share options to Directors and a PDMR, with exercise prices of £5.05 and £5.25 per ordinary share. Dr. Amy Walker received 387,872 options at £5.05, Dr. Manja Boerman received 172,000 options at £5.05, Dr. Heikki Lanckriet received 75,000 options at £5.05, and Richard Bungay received 50,000 options at £5.25. Following these grants, the total number of options held by these individuals is 753,127, representing 4.85% of the current issued share capital. The company's total issued share capital is 15,538,518 ordinary shares, and after this grant, there will be 1,354,024 options outstanding, approximately 8.71% of the issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your 4BB notes
Grant of Options
Director/PDMR Dealing
Cambridge, UK – 22 July 2026
–
4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it has granted in aggregate 684,872 options over ordinary shares of the Company, (the “
Share Options
") to certain Directors and a PDMR of the Company.
634,872 of the Share Options granted to Dr. Amy Walker, Dr. Manja Boerman and Dr. Heikki Lanckriet have an exercise price of £5.05 per ordinary share (breakdown below), being the closing mid-market price on 1 May 2026, and the remaining 50,000 Share Options granted to Richard Bungay have an exercise price of £5.25 per ordinary share, being the closing mid-market price on 21 July 2026.
Further details are set out in the Notification of Dealing Form below.
| Number of Share Options Granted | Resultant Number of Share Options Held | As a % of Current Issued Share Capital | |
|---|---|---|---|
| Dr. Amy Walker | 387,872 | 430,000 | 2.77% |
| Dr. Manja Boerman | 172,000 | 172,000 | 1.11% |
| Dr. Heikki Lanckriet | 75,000 | 101,137 | 0.65% |
| Richard Bungay | 50,000 | 50,000 | 0.32% |
| Total | 684,872 | 753,127 | 4.85% |
Certain amounts of the Share Options have been granted to Dr. Amy Walker and Dr. Manja Boerman pursuant to delayed option grants that were agreed in 2024 and 2025.
301,872 of the Share Options granted to Dr. Amy Walker and all of the Share Options granted to Dr. Manja Boerman vest annually in equal tranches over four years from 1 May 2026. 86,000 of the Share Options granted to Dr. Amy Walker will become exercisable if the volume-weighted average share price of the Company exceeds £15.00 for 30 consecutive trading days. The Share Options granted to Richard Bungay vest annually in equal tranches over four years from 21 July 2026. The Share Options granted to Dr. Heikki Lanckriet vest in full immediately on grant.
The issued share capital of the Company is 15,538,518 ordinary shares. Following the grant of the Share Options, the Company will have 1,354,024 options over ordinary shares in issue representing approximately 8.71 per cent. of the Company’s current issued share capital
.
| 1 | Details of the persons discharging managerial responsibilities / person closely associated | |
| a) | Name | 1) Dr. Amy Walker 2) Dr. Manja Boerman 3) Dr. Heikki Lanckriet 4) Richard Bungay |
| 2 | Reason for the notification | |
| a) | Position/Status | 1) Chief Executive Officer 2) Executive Chair 3) Non-executive Director 4) PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | 4basebio plc |
| b) | LEI | 213800E2DX9EAIUNCB30 |
| a) | Description of the financial instrument, type of instrument Identification code | Options over Ordinary Shares ISIN: GB00BMCLYF79 |
| b) | Nature of the transaction | Grant of Options over Ordinary Shares |
| c) | Price(s) and volume(s) | Price(s) per share (p) Volume(s) i) 505p ii) 505p iii) 505p iv) 525p i) 387,872 ii) 172,000 iii) 75,000 iv) 50,000 |
| d) | Aggregated information - Aggregated volume - Aggregated Price | See above |
| e) | Date of transaction | 21 July 2026 |
| f) | Place of transaction | Outside a trading venue |
4376666_0.png
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.